Navigation Links
Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
Date:1/10/2011

HORSHAM, Pa., Jan. 10, 2011 /PRNewswire/ -- Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company focused on dermatology and pediatrics, today announced that Mark Strobeck, Ph.D., has been appointed vice president and chief business officer. In his new role Dr. Strobeck will report to Robert Radie, president and chief executive officer, and will be responsible for managing business development, corporate strategy and financings.

"We are pleased to welcome to the Topaz management team Mark, a proven leader with a significant track record of success, who will lead our business development efforts," said Robert Radie, president and chief executive officer of Topaz. "With our lead product candidate nearing the final stage of development, we are building our commercial capabilities and interested in extending our business development reach."

Dr. Strobeck has decades of experience in the pharmaceutical and financial industry. Most recently, he served as chief business officer of Trevena, Inc., a pharmaceutical company dedicated to the discovery and development of GPCR biased ligands. Before joining Trevena he served as vice president of business development at GlaxoSmithKline (GSK) where he led the business development efforts for the company's clinical and preclinical stage assets. He also served as vice president of business development for the center of excellence for external drug discovery, a research and development division within GSK. Prior to this role Dr. Strobeck was a principal at SR One Ltd., the wholly owned venture capital arm of GSK.

Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati. He completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and has a bachelor's degree from St. Lawrence University.

About Topaz Pharmaceuticals Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for pediatric and dermatology markets. The company's lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice in children and adults which affects between six and 12 million people every year. The company has recently concluded two phase 3 studies of ivermectin for this potential indication and expects to file a new drug application this year. Topaz, headquartered in Horsham, PA, is backed by top-tier investors including Aisling Capital and Fidelity Biosciences. For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com. Contact Information E. Blair Schoeb Tel: 908-277-0386 blair@biotechcomm.com
'/>"/>

SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
4. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
5. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
6. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. TOPAZ Technologies and ML Weekes & Company Announce Partnership
8. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
9. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):